Aberrantly methylated genes represent important markers for cancer diagnosis. We describe a multiplex detection approach to efficiently quantify these markers for clinical applications such as colorectal cancer screening.
ers. The markers assayed highly discriminated colorectal neoplasia from healthy epithelia.
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Colorectal cancer (CRC) 3 remains the second most common cause of cancer mortality in the US (1 ). CRC is curable when it is diagnosed while still localized and is preventable by the detection and removal of advanced adenomas (2 ) . Conventional methods for screening CRC are either invasive or lack adequate diagnostic accuracy (3 ), necessitating the development of more user-friendly and accurate approaches. Detection of methylation markers in stool provides a promising approach for noninvasive screening of colorectal neoplasms.
Hypermethylation of CpG islands in genepromoter regions acts as a mechanism to inactivate specific gene expression and facilitates tumorigenesis of various cancers. Aberrantly methylated genes are attractive tumor markers because of their relatively high frequency in neoplasms (4 -8 ) and that they have predictable regions, CpG islands, in their promoters (9 ) to target with molecular assays. Owing to tumor heterogeneity, a panel of methylated markers is often assayed together to improve the diagnostic sensitivity of tumor detection (10 -12 ) . Ideally, methods for detecting methylated markers in bodily fluids would be able to detect minute amounts of methylated gene copies against a background of abundant unmethylated gene copies. A multiplex configuration would potentially improve assay reproducibility and reduce cost.
We describe here a novel technology, quantitative allele-specific real-time target and signal amplification (QuARTS), for multiplex detection of methylated markers. The aims of this study were to (a) test the analytical sensitivity of QuARTS for detecting lowabundance methylated gene copies against excessive background amounts of unmethylated copies and (b) assess the QuARTS technology by multiplex detection of tumor-specific methylated genes BMP3 (bone morphogenetic protein 3) 4 (6, 13 ) , NDRG4 (N-myc downstream-regulated 4) (14 ), VIM (vimentin) (15 ) , TFPI2 (tissue factor pathway inhibitor 2) (7 ), and a reference gene ACTB (␤-actin) in well-characterized tissues from patients with colorectal cancers or advanced adenomas (Ն1 cm) and from individuals with normal colonoscopies.
Materials and Methods

DESIGN OF QuARTS ASSAY
The QuARTS technology ( Fig. 1 ) (see Supplemental Fig. 1 , which accompanies the online version of this article at http://www.clinchem.org/content/vol58/ issue2) was developed by combining a polymerasebased target DNA amplification process with an invasive cleavage-based signal amplification process (16 -18 ) . Fluorescence signal generated by the QuARTS reaction is monitored in a fashion similar to real-time PCR. During each amplification cycle, 3 sequential chemical reactions occur in each assay well, with the first and second reactions occurring on target DNA templates and the third occurring on a synthetic DNA target labeled with a fluorophore and quencher dyes, thus forming a fluorescence resonance energy transfer (FRET) donor and acceptor pair. The first reaction produces amplified target with a polymerase and oligonucleotide primers, and the second reaction uses a highly structure-specific 5Ј-flap endonuclease-1 (FEN-1) enzyme reaction to release a 5Ј-flap sequence from a target-specific oligonucleotide probe that binds to the product of the polymerase reaction, forming an overlap flap substrate. In the third reaction, the cleaved There are 3 reactions sequentially occurring in each QuARTS assay, including DNA amplification (reaction 1), target probe cleavage (reaction 2), and FRET cleavage/fluorescent signal generation (reaction 3). FRET cassettes with FAM and Red dyes are used here to generate fluorescent signals at 2 distinct wavelengths.
flap binds to a specially designed oligonucleotide containing a fluorophore and quencher closely linked in a FRET pair such that the fluorescence is quenched (FRET cassette). The released probe flap hybridizes in a manner that forms an overlap flap substrate that allows the FEN-1 enzyme to cleave the 5Ј-flap containing the fluorophore, thus releasing it from the quencher molecule. The released fluorophore generates fluorescence signal to be detected. During the second and third reactions, the FEN-1 reaction can cut multiple probes per target, generating multiple 5Ј-flaps and multiple FRET cassettes per cleaved 5Ј-flap, giving rise to additional linear signal amplification to the overall reaction. We designed multiple assay configurations using this technology for methylated DNA analysis. Each assay was designed to detect up to 3 genes reporting to 3 distinct fluorescent dyes.
ASSAY EVALUATION WITH A MODEL SYSTEM
To assess the analytical performance of the QuARTS assay for detecting methylated markers, we performed 3 dilution experiments that addressed dynamic range, cross-reactivity, and analytical sensitivity with an engineered plasmid containing DNA sequences representing bisulfite-treated methylated and unmethylated VIM. The first experiment used a QuARTS duplex assay to assess plasmids with methylated and unmethylated VIM sequences that were 10-fold serially diluted from 10 -10 5 copies per microliter ( Fig. 2 ) (see online Supplemental Fig. 2 ) to determine dynamic range. The second experiment assessed cross-reactivity between the methylated and unmethylated VIM assays using 10 5 copies of input unmethylated and methylated VIM, respectively (Fig. 2, Fig. 3 ). The third experiment measured the analytical sensitivities of these assays by detecting methylated VIM spiked in unmethylated VIM and vice versa at ratios of 10%, 1.0%, 0.1%, and 0.01% (Fig. 3) . All plasmids were digested with restriction enzyme EcoRI to generate 0.3-to 1.0-kb double-stranded linear sequences. Each gene copy is equal to 2 strands. The same type of evaluation was routinely used to evaluate QuARTS assays of other methylated markers, as well (data not shown).
We performed duplex VIM QuARTS reactions ( Fig. 1 ) using 500 nmol/L of each primer and detection probe, 300 nmol/L FAM and Red FRET cassettes (Hologic), 6 .675 ng/L Cleavase® (Hologic), 1 U GoTaq® DNA polymerase (Promega), 10 mmol/L 3-(nmorpholino) propanesulfonic acid (MOPS), 7.5 mmol/L MgCl 2 , and 250 mol/L of each dNTP. QuARTS cycling conditions consisted of 95°C for 3 min followed by 10 cycles of 95°C for 20 s, 67°C for 30 s, and 70°C for 30 s. After completion of the 10 cycles, an additional 37 cycles at 95°C for 20 s, 53°C for 1 min, and 70°C for 30 s were performed. Primers and probe sequences for detecting methylated and unmethylated VIM are listed in Table 1 .
ASSAY EVALUATION WITH TISSUE SAMPLES
We further evaluated the QuARTS technology using DNA from 91 colorectal tissue samples, including 37 cancers, 25 adenomas (Ն1 cm), and 29 healthy epithe- Table 1 . The TFPI2 assay had a specific invasive oligo ( Table 1 ). The forward primers of BMP3, NDRG4, VIM, and ACTB assays also served as invasive oligos. Primers and probe of each methylated assay covered 7-10 CpG sites to improve assay specificity, but primers and probe of ACTB assay did not cover any CpG sites to allow unbiased amplification. Each plate consisted of bisulfite-treated DNA samples, standard curve samples, positive and negative controls, and water blanks. Standard curves were made of 10-fold serially diluted engineered plasmids with corresponding gene inserts. We used bisulfite-treated HT-29 cell line DNA (ATCC) and human genomic DNA (Merck) as positive and negative controls. We determined DNA strand number by comparing the quantification cycle (Cq) of target gene to the standard curve of that assay.
EVALUATION OF ASSAY REPRODUCIBILITY
One bisulfite-treated in vitro methylated DNA (Zymo Research) sample was tested 8 times in triplicate using 8 different PCR plates. The samples were assessed using 2 triplex assays, with ACTB, BMP3, and TFPI2 in the first assay and ACTB, NDRG4, and VIM in the second assay. Reaction conditions, oligos (Table 1) , and standard curves were as described above. We calculated the CV based on the mean value of each triplicate to determine the reproducibility of each methylated marker and reference gene between plates.
DATA ANALYSIS
We determined the copy number of each gene in the multiplex assay by comparing to a standard curve using known copies of plasmid DNA. To determine percent methylation for each marker, we divided the strand number of the methylated gene by the ACTB strand number and multiplied by 100. We calculated the positive percent agreement (diagnostic sensitivity) by dividing the detected positives by the known clinically positive samples and multiplying by 100, and the negative percent agreement (diagnostic specificity) by dividing the detected negatives by the known healthy controls and multiplying by 100. Data were presented 2 ways based on how the threshold was determined: the first used the best-fit model and the second used the mean of the normal data plus 3 SDs. An ROC curve was constructed to compare methylation level in cancers or adenomas vs healthy subjects for each of the 4 markers and their combination, and area under the curve (AUC) value was also calculated for each curve. We used the Tukey-Kramer test to compare methylation levels between each of the 3 different tissue groups and between sex groups for all 4 methylated genes. Linear regression analysis was performed to analyze the association between age and percent methylation for all 4 methylated genes in the healthy, cancer, and adenoma groups. We assessed the linear regression analyses output for statistical significance of the slope in conjunction with the magnitude of the coefficient of determination (R 2 ). We calculated the CV by dividing SD by mean. All statistical analyses were performed using SAS JMP 8.0 software (SAS).
Results
ANALYTICAL PERFORMANCE OF QuARTS IN MODEL SYSTEM
This study was conducted to test the dynamic range, analytical sensitivity, and specificity of the QuARTS reaction using a duplex assay of methylated and unmethylated VIM assays as an example. We used engineered plasmids containing bisulfite-treated methylated and unmethylated VIM sequence inserts as model systems. In the first experiment, duplex QuARTS assays could linearly quantify 10 -100 000 strands of methylated (Fig. 2, online Supplemental Fig. 2 ) and unmethylated (Fig. 2, online Supplemental Fig. 2) VIM. In the second experiment, no cross-reactivity was observed when methylated and unmethylated assays were used to amplify excessive amounts (10 5 copies) of unmethylated and methylated genes, respectively (Fig. 2, Fig. 3 ). Methylated and unmethylated reactions in the duplex assay specifically detected corresponding methylated and unmethylated VIM strands only. In the third experiment, the duplex assay detected methylated VIM spiked in unmethylated VIM (Fig. 3A) at 0.01% (1: 10 000 ratio) when the methylated assay was used to detect methylated copies spiked into unmethylated copies at 10%, 1%, 0.1%, and 0.01% ratios, and vice versa (Fig. 3B) . Similarly, each of the methylation assays was developed in the same manner and was shown to be specific for the methylated gene sequences.
CLINICAL PERFORMANCE OF QuARTS IN COLORECTAL TISSUES
The QuARTS reaction was further validated by quantifying methylated genes BMP3, NDRG4, VIM, and TFPI2 in colorectal tissue samples. Median (range) percent methylation values of BMP3, NDRG4, VIM, and TFPI2 were 12.6% (0%-34.9%), 14.9% (0%-42.0%), 11.1% (0%-38.7%), and 21.1% (0.8%-41.4%) in colorectal cancer; 0.8% (0%-32.9%), 2.4% (0%-30.9%), 1.1% (0%-35.6%), and 16.0% (1.2%-33.5%) in advanced adenoma; and 0.03% (0%-0.5%), 0% (0%-0.6%), 0% (0%-1.2%), and 0.5% (0%-3.7%) in healthy epithelia (Fig. 4) . Percent methylation was significantly higher in cancer than in healthy epithelia for each of the 4 genes (P Ͻ 0.001 for each), higher in adenoma than in healthy epithelia for TFPI2 (P Ͻ 0.001), and higher in cancer than in adenoma for BMP3 and NDRG4 (P Ͻ 0.001 for each). Methylated markers BMP3, NDRG4, VIM, and TFPI2, respectively, detected 84%, 92%, 86%, and 92% of colorectal cancers and 68%, 76%, 76%, and 88% of advanced adenomas at a diagnostic specificity cutoff of 95%. When positive/ negative thresholds were set at mean plus 3 SDs, BMP3, NDRG4, VIM, and TFPI2, respectively, detected 84%, 89%, 84%, and 92% of colorectal cancers and 64%, 68%, 56%, and 88% of advanced adenomas at corresponding specificity cutoffs of 97%, 97%, 97%, and 100%. The combination of all 4 markers detected 100% of colorectal cancers and 96% of advanced adenomas at a diagnostic specificity of 100%.
ROC curves were constructed for each of the 4 genes ( Each dot represents 1 sample. The 95% CI of median percent methylation of each sample group is indicated with a circle on the right side of each group. If the circles between 2 groups are not overlapping, the difference of their methylation levels is significant; otherwise, it is not significant. values were 0.89, 0.91, 0.90, and 0.98 for BMP3, NDRG4, VIM, and TFPI2.
Linear regression analysis of percent methylation and age yielded statistically significant slope in the cancer group for markers BMP3 (P ϭ 0.001), NDRG4 (P Ͻ 0.001), VIM (P Ͻ 0.001) and TFPI2 (P ϭ 0.01) and in the healthy group for marker TFPI2 (P ϭ 0.03). Coefficients of determination, R 2 , were 0.17 for TFPI2 in healthy group and 0.17, 0.28, 0.28, and 0.32 for TFPI2, BMP3, NDRG4, and VIM in the cancer group, respectively. Percent methylation was not associated with sex for all 4 markers.
REPRODUCIBILITY OF QuARTS
We tested the reproducibility of the QuARTS assay by quantifying methylated BMP3, TFPI2, NDRG4, and VIM and the reference gene ACTB in 1 known positive control sample in triplicate 8 times. CVs of gene strand numbers were, respectively, 3.5%, 6.0%, 3.0%, and 4.3% for methylated BMP3, TFPI2, NDRG4, and VIM and 4.2% and 5.7% for ACTB in the 2 triplex assays. CVs of percent methylation were 3.2%, 2.7%, 3.4%, and 3.0%, respectively, for BMP3, TFPI2, NDRG4, and VIM.
Discussion
This report describes the QuARTS technology for multiplex detection of methylated gene markers. When evaluated in dilution experiments with engineered plasmid models, the QuARTS technology could linearly detect methylated DNA down to 10 copies and discriminate methylated targets within an unmethylated population of plasmids at 0.01% (1 methylated copy per 10 000 unmethylated copies). When further tested in colorectal tissues, methylation markers assayed with the QuARTS method detected most CRCs and adenomas at a specificity cutoff of 95%. These results demonstrate that QuARTS is a promising DNA amplification technology for developing diagnostic 
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tests based on the detection of low-abundance gene alterations in human specimens.
Methylated genes have been studied in various human sample types as potential approaches for cancer detection (7, 12-15, 19 -25 ) . Because genetic and epigenetic alterations are rare events in heterogeneous specimens like stool (3 ), highly sensitive assays are essential for reliably detecting low-abundance DNA markers. We have reported that tumor-derived mutations are often at Ͻ1% mutant:wild-type ratios in stool from CRC patients, and the median mutant:wild-type ratio in stool was only 0.6% with advanced adenomas from the screening setting (26 ) . Methylated-to-unmethylated ratios of tumor-specific methylated genes in stool fall within similar ranges based on our observations. Several methylation-specific approaches have been used to assay rare methylated markers in bodily media (22, (27) (28) (29) (30) (31) (32) , but most of them lack the ability of multiplex quantification at very low analyte concentrations. In contrast, the QuARTS technology incorporates both the specific multitarget cleavage function of cleavase chemistry (16 -18 ) and the quantitative property of real-time PCR to uniquely provide multiplex marker detection at analyte concentrations as low as 1 methylated copy in 10 000 unmethylated copies. This QuARTS capacity allows improved assay reproducibility and maximal discrimination value. Furthermore, for highly specific detection of methylated sequences, primers and probe of each methylated QuARTS assay were designed to cover 7-10 CpG sites. We have recently applied the QuARTS method to our new version of stool DNA testing for screening colorectal cancer and advanced adenoma, and generated good clinical performance (33 ) . Using QuARTS as an assay platform for stool DNA testing, 85% of colorectal cancers and 64% of adenomas Ͼ1 cm were detected at 90% specificity (33 ) , which represents a substantial improvement over previous stool DNA tests using less-sensitive assay methods (34 -36 ) .
In the present study, methylated markers BMP3, NDRG4, VIM, TFPI2, and their combination detected most colorectal cancers and adenomas Ͼ1 cm at high diagnostic specificity when assayed with QuARTS, which is consistent with previous reports by us and others (6, 7, (13) (14) (15) . Each of these markers can be considered for further evaluation in screening or diagnostic applications for colorectal neoplasms because of their broad coverage and early onset in the tumorigenesis of colorectal cancer. It is important to point out that BMP3, NDRG4, and VIM had negligible background in healthy tissues, which allows the potential for high specificity as required for screening applications. These markers are being considered as elements in the core panel of our next-generation stool DNA test, which is intended for colorectal cancer screening.
Because of its high analytical sensitivity and multiplex capacity, QuARTS would be attractive for application to other types of in vitro diagnostic tests. As examples: (a) the QuARTS method might be used in cancer screening/diagnostic tests by analyzing genetic and epigenetic markers in other biological media, such as blood, bile, sputum, or urine; (b) its application may help select appropriate treatment for individualized cancer therapy by accurately including or excluding patients with low-abundance predictor mutations, such as epidermal growth factor receptor mutations in non-small-cell lung cancers (37) (38) (39) and KRAS mutations in colorectal cancers (40, 41 ) ; and (c) QuARTS has potential as an assay platform in the diagnosis of infectious diseases or surveillance of food contamination by quantifying genetic markers from specific bacteria or viruses.
In summary, QuARTS technology shows great promise for use in development and performance of molecular tests. Methylated markers BMP3, NDRG4, VIM, and TFPI2 were found to discriminate CRC and adenoma from healthy tissue at high diagnostic sensitivity and specificity. Our next step is to incorporate QuARTS and these markers into a stool-based molecular test for screening colorectal cancer and precancer. 
